A lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion

Onkologie

Volumn 34, Issue 10, 2011, Pages 502-508

  Heckmann, Doreen ^a   Laufs, Stephanie ^a   Maier, Patrick ^b   Zucknick, Manuela ^c   Giordano, Frank A ^a,c   Veldwijk, Marlon R ^b   Eckstein, Volker ^d   Wenz, Frederik ^b   Zeller, W Jens ^a   Fruehauf, Stefan ^e   Allgayer, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e Paracelsus Klinik   (Germany)

Author keywords

Chemokines; Colorectal cancer; Invasion; Plerixafor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; LENTIVIRUS VECTOR; MATRIGEL; PLERIXAFOR; SHORT HAIRPIN RNA; STROMAL CELL DERIVED FACTOR 1ALPHA;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CHEMOTAXIS; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-HIV AGENTS; CELL LINE, TUMOR; CHEMOKINE CXCL12; CHEMOTAXIS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HETEROCYCLIC COMPOUNDS; HUMANS; LENTIVIRUS; NEOPLASM INVASIVENESS; RECEPTOR CROSS-TALK; RECEPTORS, CXCR4;

EID: 80054083089     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000332390     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
2. Compton CC: Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003;16:376-388. (Pubitemid 36443987)
3. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27. (Pubitemid 27050847)
4. Borner MM: Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true? Ann Oncol 1999;10:623-626. (Pubitemid 29342365)
5. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127. (Pubitemid 30398626)
6. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-120. (Pubitemid 27039446)
7. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14:171-179. (Pubitemid 38586742)
8. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23: 879-894. (Pubitemid 41170944)
9. Zeelenberg IS, Ruuls-Van SL, Roos E: The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-3839. (Pubitemid 36793074)
10. Ben-Baruch A: Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008;25:345-356. (Pubitemid 351748979)
11. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56. (Pubitemid 32225831)
12. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744-2753. (Pubitemid 46179464)
13. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, Junginger T, Berger MR, Galle PR, Moehler M: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005;11:1743-1750. (Pubitemid 40471835)
14. Shen W, Bendall LJ, Gottlieb DJ, Bradstock KF: The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001;29:1439-1447. (Pubitemid 34007619)
15. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T: CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004;64:2817-2824. (Pubitemid 38500620)
16. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW: Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44:1667-1673. (Pubitemid 30340812)
17. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, MacFarland RT, Henson GW, Calandra G: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-1262. (Pubitemid 39281506)
18. Lack NA, Green B, Dale DC, Calandra GB, Lee H, MacFarland RT, Badel K, Liles WC, Bridger G: A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005;77:427-436. (Pubitemid 40719270)
19. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC: Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730. (Pubitemid 37248839)
20. Burger JA, Peled A: CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52.
21. De CE: The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-1664.
22. Maier P, Herskind C, Barzan D, Zeller WJ, Wenz F: SNAI2 as a novel radioprotector of normal tissue by gene transfer using a lentiviral bicistronic SIN vector. Radiat Res 2010;173:612-619.
23. Maier P, Spier I, Laufs S, Veldwijk MR, Fruehauf S, Wenz F, Zeller WJ: Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase (P140K). Gene Ther 2010;17:389-399.
24. Scherr M, Battmer K, Blomer U, Ganser A, Grez M: Quantitative determination of lentiviral vector particle numbers by real-time PCR. Biotechniques 2001;31:520, 522, 524, passim.
25. Leibovitz A, Stinson JC, McCombs WB, III, McCoy CE, Mazur KC, Mabry ND: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 1976;36:4562-4569.
26. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De CE, Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77. (Pubitemid 28133082)
27. Schols D, Struyf S, Van DJ, Este JA, Henson G, De CE: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388. (Pubitemid 27469034)
28. Schols D, Este JA, Henson G, De CE: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-156. (Pubitemid 27351415)
29. De CE: Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol 2000;57:833-839.
30. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Renzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, Clark-Lewis I: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997;16:6996-7007. (Pubitemid 27520800)
31. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW: Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001;276:14153-14160.
32. Hatse S, Princen K, Vermeire K, Gerlach LO, Rosenkilde MM, Schwartz TW, Bridger G, De CE, Schols D: Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Lett 2003; 546:300-306. (Pubitemid 36782429)
33. Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller WJ, Fruehauf S: Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to imatinib and nilotinib. Leuk Lymphoma 2009;50:1676-1686.
34. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N: AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009;75:1240-1247.
35. Porecha NK, English K, Hangoc G, Broxmeyer HE, Christopherson KW: Enhanced functional response to CXCL12/SDF-1 through retroviral overexpression of CXCR4 on M07e cells: implications for hematopoietic stem cell transplantation. Stem Cells Dev 2006;15:325-333. (Pubitemid 44100011)
36. Dar A, Kollet O, Lapidot T: Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 2006;34:967-975. (Pubitemid 44080383)
37. Gassmann P, Haier J, Schluter K, Domikowsky B, Wendel C, Wiesner U, Kubitza R, Engers R, Schneider SW, Homey B, Muller A: CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia 2009;11:651-661.
38. Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling MK, Menger MD: Stromal cellderived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 2007; 9:862-870. (Pubitemid 47623426)
39. Rudmik LR, Magliocco AM: Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 2005;92:347-359. (Pubitemid 41779295)
40. Kahn J, Byk T, Jansson-Sjostrand L, Petit I, Shivtiel S, Nagler A, Hardan I, Deutsch V, Gazit Z, Gazit D, Karlsson S, Lapidot T: Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 2004;103:2942-2949. (Pubitemid 38451665)
41. Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J, Wuchter P, Dillmann F, Eckstein V, Wenz F, Goldschmidt H, Ho AD, Calandra G: A combination of granulocyte-colonystimulating factor (G-CSF) and Plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009;11:992-1001.
42. Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, Nakano K, Itami A, Kawada K, Nagayama S, Sakai Y: Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 2009;16:2645-2653.
43. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM: CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113:4341-4351.